T Cell Clinical Trials

1 recruiting

T Cell Trials at a Glance

136 actively recruiting trials for t cell are listed on ClinicalTrialsFinder across 6 cities in 26 countries. The largest study group is Phase 2 with 40 trials, with the heaviest enrollment activity in New York, Shanghai, and Guangzhou. Lead sponsors running t cell studies include Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Second Affiliated Hospital of Guangzhou Medical University, and Institute of Hematology & Blood Diseases Hospital, China.

Treatments under study

About T Cell Clinical Trials

Looking for clinical trials for T Cell? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new T Cell trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about T Cell clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 136 trials

Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Phase 2

A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis

Giant Cell Arteritis
Insel Gruppe AG, University Hospital Bern70 enrolled1 locationNCT06335888
Recruiting

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Chronic Lymphocytic Leukemia (CLL)Hairy Cell Leukemia (HCL)Non-Hodgkins Lymphoma (NHL)+2 more
National Cancer Institute (NCI)1,263 enrolled1 locationNCT01087333
Recruiting

Characterization of the Microbiome in Cutaneous T Cell Lymphoma

Cutaneous T Cell Lymphoma
Northwestern University300 enrolled1 locationNCT03932279
Recruiting
Phase 2

Photopheresis in Early-stage Mycosis Fungoides

Mycosis FungoidesCutaneous T Cell Lymphoma
Columbia University74 enrolled1 locationNCT05680558
Recruiting
Phase 2

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Advanced Systemic Mastocytosis (AdvSM)SM With an Associated Hematologic Neoplasm (SM-AHN)Mast Cell Leukemia (MCL)+1 more
Cogent Biosciences, Inc.140 enrolled42 locationsNCT04996875
Recruiting

Epidemiological Data on Mast Cell Pathologies in France

Mast Cell Disorder
Imagine Institute13,000 enrolled21 locationsNCT06186856
Recruiting
Phase 3

Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

Giant Cell Tumor of Bone
St. Louis University120 enrolled16 locationsNCT03295981
Recruiting

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

Clonal Mast Cell DiseaseKIT D816V MutationSuspected KITD816V Mutated Clonal Mast Cell Disease
Blueprint Medicines Corporation450 enrolled17 locationsNCT07143669
Recruiting
Phase 2

Study of Lacutamab in Peripheral T-cell Lymphoma

Relapse/RecurrencePeripheral T Cell Lymphoma
The Lymphoma Academic Research Organisation56 enrolled64 locationsNCT04984837
Recruiting

The VGR GCA Cohort: Ultrasound, Biopsy and Biomarkers - Novel Methods for Diagnosis, Monitoring and Prognosis in Giant Cell Arteritis.

Giant Cell Arteritis (GCA)
Vastra Gotaland Region340 enrolled1 locationNCT07246577
Recruiting
Not Applicable

Nutrition OUtReach In Systems of Healthcare

CAR-T Cell TherapyALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONFood Insecurity+1 more
University of Kansas Medical Center210 enrolled4 locationsNCT06802406
Recruiting
Phase 2

Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)

Tenosynovial Giant Cell Tumor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany20 enrolled1 locationNCT07499362
Recruiting
Phase 1

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

CD30-Positive Diffuse Large B-Cell LymphomaAnaplastic Large Cell Lymphoma, T Cell and Null Cell TypeAnaplastic Large Cell Lymphoma, ALK-Positive
Baylor College of Medicine90 enrolled2 locationsNCT06176690
Recruiting
Phase 1Phase 2

Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)

Extranodal NK T Cell LymphomaHemophagocytic Lymphohistiocytosis (HLH)
Beijing Tongren Hospital25 enrolled1 locationNCT07525466
Recruiting
Phase 1

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedPeripheral T Cell LymphomaRelapsed Peripheral T-Cell Lymphoma+4 more
Mayo Clinic21 enrolled2 locationsNCT06508463
Recruiting
Phase 2

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

Giant Cell Arteritis (GCA)
National Institute of Allergy and Infectious Diseases (NIAID)78 enrolled7 locationsNCT07108387
Recruiting
Not Applicable

Coping Skills Training for Symptom Management and Daily Steps (Step Up)

Hematopoietic Stem Cell TransplantCAR-T Cell Therapy
Duke University177 enrolled1 locationNCT06575712
Recruiting
Phase 1

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Mycosis FungoidesCutaneous T Cell Lymphoma
University of Alabama at Birmingham10 enrolled1 locationNCT05414500
Recruiting
Phase 1

Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)

Cutaneous T Cell Lymphoma
H. Lee Moffitt Cancer Center and Research Institute38 enrolled1 locationNCT07047885